
%0 Journal Article
%A Grohmann, Gary 
%T Regulatory issues in pandemic influenza vaccine development
%J Microbiology Australia
%D 2006/11/01
%V 27
%N 4
%P 172-174
%K 
%R https://doi.org/10.1071/MA06172
%U https://www.publish.csiro.au/paper/MA06172 
%X The Therapeutic Goods Administration (TGA) is responsible for the licensing of vaccines used in Australia. This includes pre-market evaluation aspects (such as assessing the quality, efficacy and safety of vaccines) and post-market aspects (such as batch release testing and the monitoring of adverse reactions). For inter-pandemic and pandemic influenza vaccines, TGA is also involved in the selection of appropriate vaccine viruses and the calibration and supply of reagents for the production of influenza vaccines. Together with industry, TGA has a responsibility to ensure that all regulatory and good manufacturing requirements (GMP) are met to ensure vaccine safety and efficacy. 
